Navigation Links
Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
Date:1/6/2012

IRVING, Texas, Jan. 6, 2012 /PRNewswire/ -- Reata Pharmaceuticals, Inc. today announced that Warren Huff, President and CEO, will present a company overview at the 30th Annual J.P. Morgan Healthcare Conference.  The presentation will take place on Tuesday, January 10, at 10:00 a.m. PST in the Elizabethan C/D Room at the Westin St. Francis Hotel in San Francisco, CA.

Mr. Huff's presentation will include an update on the development of bardoxolone methyl, a first-in-class antioxidant inflammation modulator (AIM) for patients with advanced chronic kidney disease.  He will discuss data from the recent Phase 2b BEAM trial, which was published in the New England Journal of Medicine, as well as the status of the ongoing Phase 3 BEACON trial, a global study of 2,000 patients with advanced chronic kidney disease and type 2 diabetes. 

In addition, Mr. Huff will provide an overview of the company's recently announced agreement with Abbott to jointly develop and commercialize Reata's portfolio of new AIMs worldwide.  The collaboration includes a large number of molecules in a broad range of therapeutic areas.  This is the company's second partnership with Abbott.

About Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes, and suppress NFkB, the primary regulator of inflammatory genes. Reata is developing these compounds – called antioxidant inflammation modulators (AIMs) – with the goal of one day making them available to patients suffering from a broad range of diseases associated with inflammation and oxidative stress. Reata plans to build a stand-alone, fully integrated pharmaceutical company with a worldwide medical, commercial, and regulatory presence. For more information, please visit www.reatapharma.com.

Reata Contacts

Media: Matt Middleman or David Schull, matt.middleman@russopartnersllc.com, 212-845-4272; david.schull@russopartnersllc.com, 212-845-4271

Investors: Alan Roemer, aroemer@troutgroup.com, 1-646-378-2945


'/>"/>
SOURCE Reata Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Scripps Research team discovers treatable mechanism responsible for often deadly response to flu
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health , ... its full advisory board. The board comprises leaders spanning business, technology, academia, and ... former VP of Engineering, to Chief Technology Officer. Crooks will lead strategy and ...
(Date:7/20/2017)... 2017   KCNQ2 Cure Alliance  and ... today announced that they have completed the first ... implicated in KCNQ2 epileptic encephalopathy. They also report ... case involving an additional KCNQ2 genetic mutation. ... Pairnomix entered into a collaboration to further explore ...
(Date:7/18/2017)... San Diego, CA (PRWEB) , ... July 18, ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... system. The new biosensor chip enables researchers to study the kinetics of polyhistidine-tagged ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... from the United States Patent and Trademark Office for its Patent Applications 14/858,857 ... Trademark Office’s allowances of these patent applications further expand the protection of G-CON’s ...
Breaking Biology Technology:
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):